You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ROS1 Fusions

Showing 1 - 25 of 1,266
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)

Recruiting
  • Soft Tissue Sarcoma
  • +2 more
  • Blood and tumor samples
  • Clermont-Ferrand, France
  • +9 more
Dec 8, 2021

Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)

Recruiting
  • Protein Kinase Inhibitors
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Nov 9, 2023

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)

Recruiting
  • Nonsmall Cell Lung Cancer
  • Goyang-Si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer

Recruiting
  • Thyroid Cancer
  • NTRK fusion assessment
  • Roma, Italy
    Regina Elena National Cancer Institute
Mar 31, 2023

Solid Tumors, CNS Tumors Trial in Worldwide (Entrectinib)

Recruiting
  • Solid Tumors
  • CNS Tumors
  • Orange, California
  • +38 more
Aug 24, 2022

NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

Not yet recruiting
  • Non-Small Cell Lung Cancer(NSCLC)
  • WX-0593 Tablets
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Mar 1, 2023

High Grade Glioma Trial in Phoenix (BDTX-1535)

Not yet recruiting
  • High Grade Glioma
  • Phoenix, Arizona
    St. Joseph's Hospital and Medical Center
Oct 2, 2023

NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Department of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023

Solid Tumors Trial (afatinib)

No longer available
  • Solid Tumors
  • (no location specified)
Nov 7, 2022

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)

Not yet recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Providence, Rhode Island
    Rhode Island Hospital, Brown University
Mar 2, 2023

NSCLC, Pancreatic Cancer, Locally Advanced Solid Tumor Trial in Sydney (HMBD-001, Docetaxel, Nab-paclitaxel)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 16, 2023

RET-altered Solid Tumors Trial in Shanghai (APS03118)

Recruiting
  • RET-altered Solid Tumors
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Dec 8, 2022

Advanced or Metastatic ROS1-Positive NSCLC Trial in Guangzhou (Lorlatinib)

Recruiting
  • Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's hospital
May 31, 2022

Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

Recruiting
  • Locally Advanced Solid Tumors
  • +3 more
  • Oral repotrectinib (TPX-0005)
  • Los Angeles, California
  • +27 more
Aug 9, 2022

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Tolerance of Brigatinib in Management of Rearranged CBNPC ROS1

Completed
  • Lung Cancer ROS Translocated
    • Créteil, France
      CHI Créteil
    Nov 19, 2021

    First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous

    Recruiting
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Worldwide (NVL-520)

    Recruiting
    • Locally Advanced Solid Tumor
    • Metastatic Solid Tumor
    • Orange, California
    • +18 more
    Oct 6, 2022

    Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)

    Recruiting
    • Non Small Cell Lung Cancer Metastatic
    • Aix-en-Provence, France
    • +38 more
    Aug 9, 2022

    Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

    Withdrawn
    • Non-Small Cell Lung Cancer
    • InVisionFirst-Lung ctDNA assay
    • Los Angeles, California
    • +2 more
    Sep 16, 2022

    Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic NSCLC Trial in Beijing (XZP-5955 tablets)

    Recruiting
    • Locally Advanced or Metastatic Solid Tumors
    • Locally Advanced or Metastatic Non-small Cell Lung Cancer
    • XZP-5955 tablets
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    May 17, 2022

    Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer Trial in Belgium, France (Entrectinib,

    Recruiting
    • Invasive Lobular Breast Carcinoma
    • +2 more
    • Brussels, Belgium
    • +9 more
    May 4, 2022